However, a review article on the application of IDO1 inhibitors in cancer immunotherapy indicates that studies on IDO1 inhibitors have not produced the expected benefits for cancer patients, regardless of whether they have gastrointestinal tumors. The gene discussed is IDO1; the disease is cancer.